Fred Hutch Cancer Center researchers have made a significant advance in the effort to block Epstein-Barr virus (EBV), a widespread infection that affects about 95% of people worldwide and is linked to several cancers, neurodegenerative conditions, and other long-term illnesses. This breakthrough, detailed in the latest issue of Cell Reports Medicine, offers a novel approach to preventing EBV infection by developing human antibodies designed to neutralize the virus before it can infect crucial immune cells.
For decades, EBV has presented a formidable challenge to medical science. Unlike many viruses that target specific cell types, EBV exhibits a remarkable ability to infect a broad spectrum of B cells, a vital component of the immune system. This broad infectivity, coupled with the virus’s latency and its association with severe health outcomes, has made the development of effective antiviral therapies exceptionally difficult. The Fred Hutch team’s innovative strategy, leveraging a specialized mouse model, has yielded a critical step forward in overcoming these long-standing obstacles.
A Novel Approach to Neutralizing a Ubiquitous Virus
The cornerstone of this research lies in the creation of new monoclonal antibodies. These are laboratory-produced molecules designed to mimic the protective antibodies naturally produced by the human immune system. The Fred Hutch team engineered mice to produce human antibodies, a crucial step in generating antibodies that are less likely to be rejected by the human immune system. This approach sidesteps a common pitfall in antibody development, where antibodies derived from non-human sources can trigger adverse immune reactions, limiting their therapeutic potential.
The researchers meticulously focused on two key viral proteins that EBV utilizes to gain entry into human cells: gp350 and gp42. The gp350 protein acts as a molecular handshake, enabling the virus to attach to the surface of human cells. Following attachment, the gp42 protein facilitates the fusion of the viral envelope with the cell membrane, allowing the virus to penetrate and establish an infection. By targeting these critical entry points, the developed antibodies aim to disrupt the virus’s ability to infect host cells.
"Finding human antibodies that block Epstein-Barr virus from infecting our immune cells has been particularly challenging because, unlike other viruses, EBV finds a way to bind to nearly every one of our B cells," explained Andrew McGuire, PhD, a biochemist and cellular biologist in the Vaccine and Infectious Disease Division at Fred Hutch. "We decided to use new technologies to try to fill this knowledge gap and we ended up taking a critical step toward blocking one of the world’s most common viruses."
The scientific endeavor involved a systematic screening process. Using their specialized mouse model, the scientists successfully identified two distinct monoclonal antibodies that bind to the gp350 protein and an impressive eight antibodies that target the gp42 protein. This broad spectrum of antibody candidates provides multiple avenues for therapeutic intervention.
Crystal Chhan, a pathobiology PhD student in the McGuire Lab, highlighted the broader implications of the research methodology. "Not only did we identify important antibodies against Epstein-Barr virus, but we also validated an innovative new approach for discovering protective antibodies against other pathogens," she stated. "As an early-career scientist, it was an exciting finding and has helped me appreciate how science often leads to unexpected discoveries." This sentiment underscores the foundational value of the research, extending beyond EBV to potentially impact the development of treatments for a range of infectious diseases.
Pinpointing Vulnerabilities: Guiding Future Vaccine Design
Beyond the identification of neutralizing antibodies, the research team’s meticulous analysis also shed light on specific structural weaknesses of the EBV virus. These findings, supported by the expertise of Fred Hutch’s Antibody Tech Core, are invaluable for informing the design of future vaccines. By understanding precisely where antibodies can most effectively bind and disrupt viral function, scientists can develop more potent and targeted vaccine candidates.
In the culmination of their laboratory testing, one of the gp42-targeting antibodies demonstrated remarkable efficacy, completely preventing EBV infection in the engineered mice. This complete blockade signifies a major breakthrough, suggesting the potential for a highly effective preventative therapy. Furthermore, a gp350-targeting antibody provided significant partial protection, indicating that targeting this protein also offers a valuable therapeutic strategy, potentially in combination with other approaches.
Addressing a Critical Unmet Need in Transplant Medicine
The implications of this research are particularly profound for individuals undergoing solid organ or bone marrow transplants. In the United States alone, over 128,000 people receive such life-saving procedures annually. A common requirement for these patients is the use of immunosuppressive drugs, which, while essential to prevent organ rejection, unfortunately, create a fertile ground for EBV to reactivate and proliferate unchecked.
Currently, there is a significant void in targeted therapies that can effectively prevent EBV-related complications in this vulnerable population. One of the most serious sequelae of uncontrolled EBV infection post-transplant is post-transplant lymphoproliferative disorders (PTLD). PTLD is a severe form of lymphoma that can be life-threatening, and it is most frequently driven by EBV.
"Post-transplant lymphoproliferative disorders (PTLD), most of which are EBV-associated lymphomas, are a frequent cause of morbidity and mortality after organ transplantation," noted Rachel Bender Ignacio, MD, MPH, an associate professor and infectious disease physician at Fred Hutch and the University of Washington School of Medicine. "Preventing EBV viremia has strong potential to reduce the incidence of PTLD and limit the need to reduce immunosuppression, thereby helping preserve graft function while improving overall patient outcomes. Effective prevention of EBV viremia remains a significant unmet need in transplant medicine."
The risk of EBV exposure in transplant recipients stems from various sources. Donor organs can carry a latent form of the virus, which can become active under immunosuppression. In individuals previously infected with EBV, the weakened immune system can allow the dormant virus to reactivate and multiply. Children who receive transplants are especially susceptible, as many have not yet been exposed to EBV, meaning their immune systems have no prior experience in controlling the virus.
A Vision for Preventive Antibody Therapy
The Fred Hutch research team envisions a future where these newly developed monoclonal antibodies could be administered as an infusion. This therapy would serve as a prophylactic measure, preventing EBV infection in individuals at high risk or preventing reactivation in those already carrying the virus. The potential benefits are far-reaching, including a significant reduction in the incidence of PTLD and other EBV-associated complications, thereby improving the quality of life and survival rates for transplant recipients.
The path from laboratory discovery to clinical application is rigorous. Fred Hutch has already taken steps to protect its intellectual property related to these groundbreaking antibody discoveries. Dr. McGuire and Ms. Chhan are actively collaborating with other researchers and an industry partner to accelerate the translation of this research into a tangible therapeutic. The immediate next steps involve comprehensive safety testing in healthy adult volunteers, followed by carefully designed clinical trials in patient populations most vulnerable to EBV-related complications, particularly those undergoing transplantation.
"There’s momentum to advance our discovery to a therapy that would make a huge difference for patients undergoing transplant," expressed Dr. McGuire. "After many years of searching for a viable way to protect against Epstein-Barr virus, this is a significant stride for the scientific community and the people at the highest risk of complications from this virus."
The development of these potent EBV-neutralizing antibodies represents a beacon of hope, promising to alleviate the burden of this pervasive virus and its associated diseases, especially for those whose immune systems are most compromised. This advancement underscores the critical role of dedicated research in tackling global health challenges and improving patient outcomes.
